Heartflow, Inc.: management transactions · United States · SEC (Form 4)

About Heartflow, Inc.

Heartflow, Inc. is a U.S.-based medical technology company listed on the Nasdaq market (ticker: HTFL) and headquartered in Mountain View, California, United States. For French- and Belgian-speaking investors, Heartflow represents a digital health and medtech platform focused on diagnosing and managing coronary artery disease (CAD), one of the world’s leading causes of death. The company was originally built around the scientific work of Stanford professors Charles A. Taylor and Christopher K. Zarins, and it has since evolved into a data- and AI-driven cardiovascular software business that uses advanced imaging and computational modeling to deliver non-invasive insights from coronary CT angiography (CCTA). Heartflow’s core commercial proposition is its proprietary platform, which converts a standard CCTA scan into a personalized 3D model of the heart and provides clinicians with actionable analyses. The company first gained traction through Heartflow FFRCT Analysis, a non-invasive tool designed to assess how a coronary narrowing affects blood flow. Over time, Heartflow expanded beyond physiology into a broader portfolio that now includes plaque analysis and roadmap-style planning tools. This widens the use case from diagnosis alone to a more comprehensive coronary care workflow, helping physicians with risk assessment, treatment planning, and longitudinal disease management. From a competitive standpoint, Heartflow benefits from a relatively differentiated position. Its value proposition rests on a combination of AI, cloud-based image processing, clinical validation, and a growing installed base of physicians and patients. The company emphasizes its extensive peer-reviewed evidence base and its ability to deliver reproducible outputs across a large imaging dataset. In a market where cardiology workflows are increasingly moving toward precision and non-invasive decision support, Heartflow is positioned as one of the leading specialists in AI-enabled coronary care rather than a broad diversified medtech platform. Geographically, Heartflow is anchored in the United States but also operates internationally, with a footprint that extends beyond its domestic base. The business has progressively expanded its commercial and operational reach, reflecting the global nature of cardiovascular disease and the opportunity to scale its platform across healthcare systems. Recent developments point to a company in an active commercialization and product-expansion phase. In 2025, Heartflow completed a convertible notes financing and later closed its upsized initial public offering on Nasdaq. More recently, it announced additional FDA 510(k) clearance for next-generation plaque-analysis capabilities and continued to build its clinical evidence base. For investors, the name combines a clear thematic exposure to AI in healthcare, a sizable structural market opportunity, and the execution risks typical of a growth-stage medtech company operating in a regulated, adoption-sensitive environment.